AcelRx to Buy Lowell Therapeutics; Kala Expands Pipeline with Combangio Acquisition

AcelRx Pharmaceuticals and Kala Pharmaceuticals both shared acquisition news on Monday. Here’s a closer look at each of the acquisition announcements.

AcelRx was up 3.2% in premarket trading on Monday after announcing its plans to acquire privately-held Lowell Therapeutics. The deal, which has already been approved by both companies’ board of directors, is expected to close by the end of this year and is worth approximately $32.5 million plus other adjustments and net cash acquired.